You are what you eat: dietary salt intake and renin–angiotensin blockade in diabetic nephropathy  by Charytan, David M. & Forman, John P.
commentar y
Kidney International (2012) 82     257
 Angiotensin II (Ang II) contributes to the 
pathophysiology of diabetic nephropathy 
and other forms of progressive renal dis-
ease, 1 and the benefi ts of antagonizing 
Ang II activity in the treatment of nephro-
pathy due to type 2 diabetes have been 
established for more than a decade. 2 – 4 Th e 
renin – angiotensin system (RAS) plays 
a similarly important role in the patho-
physiology of cardiovascular disease. 5 
 Although dietary sodium loading sup-
presses the systemic RAS, resulting in 
lower plasma renin, Ang II, and aldoster-
one levels, a high-sodium diet is also 
associated with an increased risk of car-
diovascular disease. 6 Th is apparent para-
doxical eff ect of sodium (suppression of 
the systemic RAS but exacerbation of 
cardio vascular risk) may be explained, in 
part, by the muted eff ects of sodium load-
ing in some people, such as those with 
hypertension and type 2 diabetes. 7 Such 
patients have RAS activation, both 
systemically and at the tissue level (for 
example, heart, kidney), that does not 
suppress normally on a high-sodium diet. 
Moreover, short-term studies in both 
experimental animals and humans dem-
onstrate that a high-sodium diet blunts 
the benefi cial eff ects of therapy with angi-
otensin-converting enzyme (ACE) inhib-
itors on proteinuria and left  ventricular 
hypertrophy. 8 It was therefore unsurpris-
ing that a high-sodium diet was associated 
with greater proteinuria and faster pro-
gression to end-stage renal disease in 
hypertensive patients with proteinuria, as 
was recently shown in patients treated 
with an ACE inhibitor in the Ramipril 
Effi  cacy in Nephropathy trial. 9 Th ese data 
suggest that both inhibition of Ang II 
and control of dietary sodium intake are 
important factors in the treatment of 
chronic kidney disease ( Figure 1 ). 
 Nevertheless, the long-term impact of 
dietary sodium on the effects of angi-
otensin inhibition remain poorly studied. 
In this context, the study by Lambers 
Heerspink  et al. 10 (this issue) provides 
intriguing new data. The authors con-
ducted a  post hoc analysis of 1177 patients 
(36 % of those enrolled) with type 2 dia-
betic nephropathy in the RENAAL 4 and 
IDNT 3 trials for whom measurements of 
24-hour urinary sodium excretion were 
available. Th ey found that the eff ect of 
angiotensin receptor blocker (ARB) ther-
apy on renal and cardiovascular outcomes 
varied according to sodium intake. Both 
blood pressure and albuminuria were 
decreased by the ARB to a greater extent 
in those with lower compared with higher 
sodium intake. More importantly, the 
benefits of ARB therapy for renal out-
comes (defi ned as a doubling of serum 
creatinine or progression to end-stage 
renal disease) and cardiovascular out-
comes (defi ned as cardiovascular death, 
myocardial infarction, stroke, or hospi-
talization for heart failure or coronary 
revascularization) were significantly 
greater in those at the lowest compared 
with the highest tertile of sodium intake. 
Specifi cally, the ARB was associated with 
signifi cantly reduced risks of renal and 
cardiovascular events, 43 and 37 % , respec-
tively, if sodium intake was low. In con-
trast, ARB therapy was associated with 
non-significantly higher risks when 
sodium intake was high. Th ese data sup-
port the idea that renal and cardiovascular 
protection is maximized when both 
salt restriction and renin – angiotensin 
blockade are combined. 
 The authors ’ findings are intuitively 
compelling, and the analysis has several 
strengths, including the use of high-
quality, randomized trial data with suffi  -
cient numbers of patients and outcomes 
to assess meaningful clinical end points. 
Furthermore, the collection of urine every 
6 months allowed for the analysis of mean 
sodium intake throughout the trial rather 
than at baseline (or a single time point) as 
in most other studies of sodium intake. 
 However, a number of issues regarding 
the study methodology merit considera-
tion. Although the authors analyzed data 
from two randomized trials, only the 
assignment to ARB vs. control was rand-
omized. Sodium intake was not rand-
omized, and there were many signifi cant 
and clinically important diff erences in 
baseline characteristics at the extremes of 
intake. Compared with the lowest tertile 
of intake, for example, patients in the 
highest tertile were more likely to be 
female (46.9 vs. 20.9 % ) and white (54.6 vs. 
42.8 % ) and have a lower estimated 
glomerular fi ltration rate (GFR) (42.2 vs. 
45.6  ml / min per 1.73  m 2 ), a lower body 
weight (85.4 vs. 91.9  kg), and a higher uri-
nary albumin-to-creatinine ratio (1905 vs. 
1173  mg / g). Th e greater distribution of 
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important risk factors in those with higher 
salt intakes suggests that the sickest 
patients — possibly those least able to 
respond to intervention — were most likely 
to have a high salt intake. Th is could be 
one critical factor underlying the greater 
benefi ts of ARB therapy observed in those 
with lower salt intakes. In fact, careful 
scrutiny of Lambers Heerspink  et al. ’ s 
Kaplan – Meier curves raises that possibil-
ity: in ARB-treated patients, the major 
diff erences in cardiovascular and renal 
event rates among the diff erent sodium 
intake groups occur during the fi rst year, 
with relatively equal event rates during 
subsequent years. 10 In addition, the 
authors did not control for most of the 
potential confounding factors. Although 
adjustment for one factor (specifi cally, 
baseline estimated GFR or urea excretion) 
did not change the interpretation of the 
main fi ndings, fully adjusted multivariable 
models (controlling for age, sex, ethnicity, 
weight, baseline estimated GFR, blood 
pressure, urinary protein excretion, and 
whether patients came from the IDNT or 
RENAAL) should have been performed. 
Such data would have provided greater 
confi dence that the results are valid and 
do not simply refl ect confounding by an 
asymmetric distribution of comorbidity. 
 An additional concern is that the sig-
nificant differences in benefit derived 
from ARB therapy observed at diff erent 
levels of sodium intake were largely driven 
by a higher risk of cardiovascular (hazard 
ratio 1.25, 95 % confi dence interval 0.89 –
 1.75) and renal events (hazard ratio 1.37, 
95 % confi dence interval 0.96 – 1.96) asso-
ciated with ARBs compared with control 
therapy in those in the highest tertile of 
sodium intake. As above, these fi ndings 
could simply refl ect confounding due to 
baseline imbalances. For example, the 
well-known hemodynamic eff ect of ARB 
initiation (resulting in a decline in GFR) 
may have been more clinically dramatic 
in patients with a lower baseline estimated 
GFR, resulting in a greater frequency of 
renal events. However, if the apparent 
adverse eff ects of ARB therapy in patients 
consuming a high-sodium diet are not 
spurious observations resulting from 
uncontrolled confounding, then this 
fi nding suggests the intriguing possibility 
that ARBs are helpful in people with a 
low sodium intake, but potentially 
harmful when sodium intake is high. Th e 
mechanism for such an eff ect is uncertain. 
Although the authors provide rationale 
for a blunted eff ect of ARBs in patients 
who consume a high-sodium diet, they 
do not provide an explanation for the 
worse outcomes, albeit not statistically 
signifi cant, that were observed. 
 Although fl awed, the study by Lambers 
Heerspink and colleagues 10 confirms 
prior work suggesting that both sodium 
restriction and blockade of the renin –
 angiotensin system are benefi cial, and it 
should serve as a reminder to clinicians 
not to ignore diet as a modifi able cardio-
vascular and renal risk factor. In the 
context of decades of research into the 
important roles that sodium intake and 
Ang II play in the pathogenesis of renal 
and cardiovascular disease, this study 
should increase clinicians ’ comfort in rec-
ommending dietary sodium restriction 
for their patients with diabetic nephropa-
thy on ARBs, lest a high sodium intake 
abrogate the protective eff ects. Th e study 
also raises intriguing new questions about 
the mechanisms of the interaction 
between sodium intake and ARBs and 
raises some concern that ARBs may be 
harmful in some patients. Additional 
mechanistic studies and randomized trials 
are clearly warranted. In short, this study 
reminds us how much further there is to 
go in understanding the full potential 
of our therapeutic armamentarium in 
diabetic kidney disease. 
 DISCLOSURE 
 JPF is a deputy editor of nephrology at 
UpToDate Inc. 
 ACKNOWLEDGMENTS 
 David M. Charytan is supported by a 
Carl S. Gottschalk award from the American 
Society of Nephrology and grant 5 R21 
DK089368-02 from the National Institute 
of Diabetes and Digestive and Kidney 
Diseases. John P. Forman is supported by 
grants 5 R01 HL105440-03 and 5 R01 
HL101122-02 from the National Heart, 
Lung, and Blood Institute. 
 REFERENCES 
 1 .  Ruster  C ,  Wolf  G .  Renin-angiotensin-aldosterone 
system and progression of renal disease .  J Am Soc 
Nephrol  2006 ;  17 :  2985 – 2991 . 
 2 .  Parving  HH ,  Lehnert  H ,  Brochner-Mortensen  J 
 et al.  The effect of irbesartan on the development 
of diabetic nephropathy in patients with 
type 2 diabetes .  N Engl J Med  2001 ;  345 : 
 870 – 878 . 
Renin
DiabeticNormal
Angiotensinogen Angiotensin I
Angiotensin II
Angiotensin receptor type 1
Angiotensin
receptor blocker
ACE inhibitor
Angiotensin-converting
enzyme
Aldosterone
Mineralocorticoid receptor
Rac-1
Sodium retention
Proliferation/fibrosis
Sodium loading
+
+
+
+
–
–
–
–
Vasoconstriction
Oxidative stress
Inflammation
Dipsogenic
 Figure 1  |  Multifactorial role of sodium in the renin – angiotensin system. Sodium loading 
typically suppresses renin synthesis, but this response may be attenuated in diabetes. Conversely, 
sodium loading can directly activate mineralocorticoid receptor activity via upregulation of Rac-1 
signaling or via increases in angiotensin-converting enzyme (ACE) activity. 
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 APOL1 variants in HIV-associated 
nephropathy: just one piece of 
the puzzle 
 Thomas  Hays 1 and  Christina M.  Wyatt 1 
 Considerable attention has been focused on how the  APOL1 / MYH9 
locus determines susceptibility to focal segmental glomerulosclerosis, 
including HIV-associated nephropathy (HIVAN). Atta and colleagues 
found that homozygosity for  APOL1 risk alleles was associated with 
many, but not all, HIVAN cases, and that  APOL1 variation failed to 
predict characteristics of disease. Their work gives important impetus 
to identify other genetic and environmental factors that may provide 
a  ‘ second hit ’ linking HIV infection to HIVAN. 
 Kidney International (2012)  82, 259 – 260.  doi: 10.1038/ki.2012.129 
 In 2008, Kopp and colleagues demon-
strated that single-nucleotide polymor-
phisms (SNPs) in a locus on chromosome 
22 determine much of the susceptibility of 
African Americans to focal segmental 
glomerulosclerosis (FSGS), a disease 
known to disproportionately affect 
blacks. 1 Although the identifi ed genetic 
locus included more than 30 genes, early 
investigation focused on  MYH9 , in part 
because of the established connection to 
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a rare mendelian disease with a glomeru-
lar phenotype. A concurrent publication 
reported a similar association with non-
diabetic end-stage renal disease, providing 
further support for the importance of this 
genetic locus in determining kidney dis-
ease susceptibility. 2 Although these stud-
ies confi rmed the strong genetic basis for 
ethnic disparities in kidney disease, they 
did not provide any insight into potential 
mechanisms, as the implicated SNPs 
were all in non-coding regions of  MYH9 . 
More recently, Genovese and colleagues 
reported that variants in the neighboring 
gene  APOL1 (see Figure 1) are more 
strongly associated with FSGS, suggesting 
that the closely linked  MYH9 SNPs are 
only sentinel markers. 3 Th e  APOL1 risk 
alleles were also shown to enhance the 
protein ’ s ability to lyse trypanosomes, the 
parasites responsible for African sleeping 
sickness, suggesting a potential mecha-
nism for the increased frequency in 
African ancestral populations. 
 Although the association of  APOL1 
variants with FSGS has been replicated in 
independent analyses, 4  APOL1 has no 
known role in the kidney. In addition, 
 MYH9 SNPs have also been associated 
with chronic kidney disease in European 
Americans lacking the  APOL1 risk alle-
les, 5 and mechanistic studies continue to 
support a possible role for  MYH9 in the 
pathogenesis of FSGS.  MYH9 ablation in 
podocytes was shown to predispose mice 
to adriamycin nephropathy, a drug-
induced model of FSGS. 6 More recently, 
 MYH9 was found to be downregulated 
in the glomeruli of patients with HIV-
associated nephropathy (HIVAN), 
a unique form of secondary FSGS that 
almost exclusively affects people of 
African descent. 7 Th ese studies suggest 
that both  APOL1 and  MYH9 may contrib-
ute to the complex pathogenesis of FSGS, 
although polymorphisms in  APOL1 have 
a more prominent infl uence on disease 
susceptibility. 3,8 
 Atta and colleagues 9 (this issue) 
consider the clinical implications of 
 APOL1 variants in a cohort of patients 
with biopsy-proven HIVAN. Among 60 
subjects with biopsy-defi ned HIVAN who 
were genotyped for the  APOL1 G1 and G2 
polymorphisms, more than one-third had 
zero or one risk allele. When these sub-
jects were compared with subjects with 
two risk alleles,  APOL1 variation was not 
associated with the histologic pattern of 
injury or with renal survival. Th e latter 
fi nding is in contrast to previous reports 
in patients with idiopathic FSGS and in 
HIV-positive patients with other forms of 
kidney disease, 4,10 but it is consistent with 
a smaller study of patients with biopsy-
proven HIVAN. 8 Although both studies 
may have been underpowered to detect a 
small diff erence in renal survival, it is also 
possible that diff erences were masked by 
the aggressive natural history of HIVAN. 
Overall, more than half of the subjects in 
the current study progressed to end-stage 
renal disease, and that proportion was 
slightly higher among those with two risk 
